Psychedelics are being investigated for neuroplasticity, inflammation, and mood effects that could help protect the aging brain and support healthier cognitive aging

Psychedelics are being investigated as potential tools to protect the aging brain by promoting neuroplasticity, reducing inflammation, and improving depression, anxiety, and trauma-related symptoms that can worsen cognitive decline. Interest centers on whether these compounds could support healthier aging rather than only treating end-of-life distress or major psychiatric illness. Research attention often focuses on psilocybin and LSD for their effects on serotonin signaling and brain connectivity, with ketamine and MDMA sometimes discussed in adjacent therapeutic contexts. The central question is whether short, guided psychedelic interventions can produce durable changes in mood, cognition, and social engagement that matter for older adults. This line of inquiry matters because aging populations face rising rates of dementia, loneliness, and treatment-resistant depression, while current options remain limited. Scientific caution remains important because evidence in older adults is still early, mechanisms are not fully established, and safety depends on screening, supervision, and careful clinical design.